<DOC>
	<DOCNO>NCT00702052</DOCNO>
	<brief_summary>This study evaluate safety efficacy daily , oral dose 10 mg RAD001 patient Mantle Cell Lymphoma refractory intolerant Velcade® therapy receive least one prior antineoplastic agent Velcade® , either separately combination Velcade® ( see inclusion criterion ) . Intolerance Velcade® therapy determine study investigator base clinical evaluation . Patients consider refractory Velcade® document radiological progression within 12 month last dose Velcade® give alone , within 12 month last dose last component combination therapy include Velcade® .</brief_summary>
	<brief_title>Safety Efficacy RAD001 Patients With Mantle Cell Lymphoma Who Are Refractory Intolerant Velcade® Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Adult patient ( &gt; 18 year old ) Mantle Cell Lymphoma confirm central pathology review ( archival diagnostic tumor specimen require ) Patients mantle cell lymphoma document refractory disease bortezomib ( Velcade® ) document intolerance Velcade® therapy . Intolerance Velcade® determine study investigator base clinical evaluation . Patients consider refractory Velcade® document radiological progression within 12 month last dose Velcade® give alone , within 12 month last dose last component combination therapy include Velcade® ) . Patients consider refractory Velcade® , Velcade® part combination treatment disease . Patients must receive least one prior antineoplastic agent , Velcade® either separately combination bortezomib ( Velcade® ) . At least one site measurable nodal disease baseline &gt; 2.0 cm long transverse diameter clearly measurable least two perpendicular dimension , determine CT scan ( MRI , CT scan perform ) ECOG performance status = 0 , 1 2 Life expectancy ≥ 3 month Adequate bone marrow , liver renal function Platelets ≥ 75 x 109/L ( untransfused platelet ) Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include chemotherapy , radiation , antibody , target therapy etc . ) eligible Previous treatment mTOR inhibitor ( e.g . everolimus , sirolimus , temsirolimus , etc ) Patients prior allogeneic stem cell transplant Grade 3 4 unresolved toxicity prior antineoplastic therapy Currently take investigational agent receive investigational drug within 4 week start study drug Patients CNS lymphoma eligible ; head MRI ( CT MRI available ) require prior study entry Use chronic , systemic corticosteroid another immunosuppressive agent , except prednisone ≤ 20 mg daily ( equivalent ) adrenal insufficiency ( must stable dosage regimen ≥ 4 week prior first treatment RAD001 ) HIV positive patient eligible ; ( HIV test require study entry ; review previous medical record require ) Uncontrolled hyperlipidemia ( ≥ Grade 3 hyperlipidemia despite optimal supportive medical therapy ) Active , bleed disorder major surgery within 4 week start study drug Severe and/or uncontrolled medical condition symptomatic congestive heart failure ( NYHA Class III IV ) , unstable angina , myocardial infarction within 6 month study start , severely impaired lung function , cirrhosis , chronic active/persistent hepatitis . History another primary malignancy ≤ 3 year prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>Mantle Zone Lymphoma</keyword>
	<keyword>Refractory Lymphoma</keyword>
	<keyword>Aggressive Lymphoma</keyword>
	<keyword>PILLAR-1</keyword>
</DOC>